MedTrace Logo

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

NCT06960954 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2025-05-07

No results posted yet for this study

Summary

The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients.

Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT.

Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).

Conditions

  • Hepato Cellular Carcinoma (HCC)
  • Portal Vein Tumour Thrombosis

Interventions

DIAGNOSTIC_TEST

Prothrombin induced by vitamin K absence II (PIVKA-II)

Serum PIVKA-II level will be measured in HCC patients with and without PVTT.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Rania M Elkafoury, MD · Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2025-12-15
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06960954 on ClinicalTrials.gov